Strand was founded by biological engineers working at MIT. Building on the idea of creating smart therapies capable of making sophisticated decisions, they sought to apply this concept to the emerging field of mRNA therapeutics. Strand’s mRNA programming technology promises to make mRNA therapies safer and more effective by programming the location, timing and intensity of therapeutic protein expression inside a patient’s body via mRNA-encoded logic circuits. These circuits have the ability to implement cell-type specific expressions by sensing and classifying the unique mRNA expression signatures of cells and control the dosage of protein expression through responses to exogenously administered small molecules.